Skip to main content
Signal8

eFFECTOR Therapeutics, Inc. (EFTR)

eFFECTOR Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, focused on devising innovative selective translation regulator inhibitors to treat various cancers. The company's primary investigational drug, Tomivosertib, is an orally administered small molecule that targets and inhibits MNK. This compound is currently undergoing a Phase 2b clinical study for patients diagnosed with metastatic non-small cell lung cancer. Furthermore, eFFECTOR is progressing with Zotatifin, another small-molecule therapeutic designed to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 2 clinical trials, exploring its efficacy in treating different solid tumors. A strategic alliance with Pfizer Inc. supports eFFECTOR's work on developing additional eIF4E inhibitors. Founded in 2012, eFFECTOR Therapeutics, Inc. maintains its operational base in Solana Beach, California.

Sector: Biotechnology

Industry: Biotechnology

eFFECTOR Therapeutics, Inc. logo

eFFECTOR Therapeutics, Inc.

OTC:EFTRHealthcare
$0.0002
CLOSED
Mkt Cap$941
EV-
Float4.67M
O/S4.71M
VOL712 sh
$ Vol$0
RVOL1.86×
Inst Own-
SI0.1%
Net Cash/Sh-
EarningsNov 17 · Today
Dilution
eFFECTOR Therapeutics, Inc. logoOTC:EFTRClosed$0.0002
Short interest (FINRA)
0.1%
Oct 30 (18d)

Float 4.67M · FMP free float

5.7K
Oct 30 (18d)prev 5.7K– 0.0%
32.34
Oct 30 (18d)prev 3.93▲ 722.9%
Borrow (IBKR)

The cost to borrow EFTR shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
No fails on record for 16–31 Oct 2026.
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 20265.7K sh
Oct 15, 20265.7K sh
Sep 30, 20265.7K sh
Sep 15, 20265.7K sh
Aug 31, 20265.7K sh

A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume

FINRA publishes no off-exchange short volume for this symbol.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for EFTR: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 5,725 EFTR shares were sold short (0.12% of a 4.67M-share float, 32.34 days to cover).